A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

Syma Iqbal, Heinz Josef Lenz, David R Gandara, Stephen I. Shibata, Susan Groshen, Timothy W. Synold, Edward M. Newman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume72
Issue number1
DOIs
StatePublished - Jul 2013

Fingerprint

oxaliplatin
docetaxel
Maximum Tolerated Dose
Esophagus
Tumors
Hypophosphatemia
Gastritis
Neutropenia
Liver
Toxicity
Liver Diseases
Ovary
Diarrhea
Neoplasms
Hypersensitivity

Keywords

  • Docetaxel
  • Oxaliplatin
  • Oxaliplatin and Docetaxel
  • Phase I

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. / Iqbal, Syma; Lenz, Heinz Josef; Gandara, David R; Shibata, Stephen I.; Groshen, Susan; Synold, Timothy W.; Newman, Edward M.

In: Cancer Chemotherapy and Pharmacology, Vol. 72, No. 1, 07.2013, p. 85-91.

Research output: Contribution to journalArticle

Iqbal, Syma ; Lenz, Heinz Josef ; Gandara, David R ; Shibata, Stephen I. ; Groshen, Susan ; Synold, Timothy W. ; Newman, Edward M. / A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. In: Cancer Chemotherapy and Pharmacology. 2013 ; Vol. 72, No. 1. pp. 85-91.
@article{faac6a17d6774830a4aaa7d1c205f858,
title = "A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors",
abstract = "The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.",
keywords = "Docetaxel, Oxaliplatin, Oxaliplatin and Docetaxel, Phase I",
author = "Syma Iqbal and Lenz, {Heinz Josef} and Gandara, {David R} and Shibata, {Stephen I.} and Susan Groshen and Synold, {Timothy W.} and Newman, {Edward M.}",
year = "2013",
month = "7",
doi = "10.1007/s00280-013-2171-4",
language = "English (US)",
volume = "72",
pages = "85--91",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

AU - Iqbal, Syma

AU - Lenz, Heinz Josef

AU - Gandara, David R

AU - Shibata, Stephen I.

AU - Groshen, Susan

AU - Synold, Timothy W.

AU - Newman, Edward M.

PY - 2013/7

Y1 - 2013/7

N2 - The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.

AB - The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.

KW - Docetaxel

KW - Oxaliplatin

KW - Oxaliplatin and Docetaxel

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=84879795373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879795373&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2171-4

DO - 10.1007/s00280-013-2171-4

M3 - Article

VL - 72

SP - 85

EP - 91

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -